Biosimilars· June 24, 2026 · 17 min read
Darzalex Biosimilar Tracker: SC vs IV Formulations and the 2029 Market Entry Window
By Ran Chen#Biosimilars#Purple Book#Oncology
Topic
Medical Benefit
Medical benefit drug coverage, buy-and-bill billing, HCPCS J-codes, provider-administered drugs, and medical benefit prior authorization.
Pricing & Access· June 24, 2026 · 26 min read
J&J Janssen Portfolio Dossier: Stelara Biosimilars and Oncology Assets
By Ran Chen#Purple Book#Orange Book#Biosimilars
Pricing & Access· June 24, 2026 · 26 min read
Roche Genentech Portfolio Dossier: Subcutaneous Biologic Transitions
By Ran Chen#Purple Book#Biosimilars#J-Code
Pricing & Access· June 10, 2026 · 10 min read
Bispecific antibody access landscape for myeloma and lymphoma
Pricing & Access· June 10, 2026 · 9 min read
CAR-T cell therapy access landscape: seven products in 2026
By Ran Chen#CAR-T#Oncology#Prior Authorization
Pricing & Access· June 10, 2026 · 10 min read
PD-1/PD-L1 checkpoint inhibitor access landscape in 2026
Pricing & Access· June 6, 2026 · 10 min read
GLP-1 pharmacy vs medical benefit: routing, cost-sharing, and PA impact
By Ran Chen#GLP-1#Pharmacy Benefit#Medical Benefit
Specialty· May 31, 2026 · 10 min read
Pharmacy benefit lockout: when route-of-administration shifts create coverage gaps
Pipeline· May 31, 2026 · 10 min read
Veligrotug vs Tepezza thyroid eye disease access guide
By Ran Chen#PDUFA Date#FDA Approval#Ophthalmology
Pricing & Access· May 27, 2026 · 13 min read